

T

by khurshid khan

Submission date: 26-Aug-2024 07:57AM (UTC+0530)

Submission ID: 2438052535

File name: JKSU_Revised_25.08.24.docx (10.19M)

Word count: 5019

Character count: 29995

1 **Anti-aggregation potential of polyphenols from Ajwa date palm (*Phoenix dactylifera*):**
2 **An in-silico analysis**

3 **Abstract:**

4 **Background:** Amyloid β (A β) fibril agglomeration is crucial in Alzheimer's disease (AD)
5 etiology, leading to significant harm to the central nervous system. Polyphenols have been
6 investigated for their capacity to hinder A β agglomeration. **Objective:** This investigation
7 aimed to assess the potential of Ajwa date palm (*Phoenix dactylifera*)-based bioactives to
8 bind and disrupt resilient A β ₁₋₄₂ fibrils through in-silico studies. **Methods:** The primary
9 phytochemicals present in date palms were subjected to molecular docking with three
10 different conformers of A β ₁₋₄₂ as well as Absorption, Distribution, Metabolism, Excretion,
11 and Toxicity (ADMET) analysis. The stability of the system was assessed through molecular
12 dynamics (MD) simulation. **Results:** It was noted that Diosmetin, Rutin, and Genistein are
13 effectively bound to 2BEG, 2MXU, and 2NAO fibrils, respectively, with docking energies
14 ranging from -7.2 to -8.2 kcal mol⁻¹. Diosmetin, Rutin, and Genistein show notable
15 pharmacokinetic variability, with LogP values from -1.69-2.58, with 1-6 rotatable bonds, and
16 total polar surface areas (TPSA) between 112.52 and 240.90 Å², important for drug
17 candidacy evaluation. Their ADMET properties include solubility values of -3.238 to -3.595
18 mol/L, intestinal absorption of 23.4-93.4%, and VD_{ss} ranging from 0.094-1.663 L/kg. The
19 ensuing MS simulations spanning 100 ns, illuminated the establishment of a robust peptide-
20 chemical complex. Hydrophobic interactions, ionic and hydrogen bonds play a critical role in
21 the ligand binding with their respective targets. **Conclusions:** These findings underscore the
22 potential of these botanicals as leads for developing potent A β agglomeration inhibitors.
23 However, before introducing into clinical settings, these findings need to be validated further.

24 **Keywords:** Alzheimer's disease, ADMET, Ajwa dates, Polyphenols, Molecular docking,
25 Molecular Dynamics

26

27

1 Abbreviations

2	AD	Alzheimer's disease
3	A β	Amyloid β
4	ADT	AutoDock Tools
5	CGenFF	CHARMM General Field
6	GROMACS	Groningen Machine for Chemical Simulations
7	K _d	Dissociation coefficient
8	LGA	Lamarckian Genetic Algorithm
9	MD	Molecular dynamics
10	MMFF	Merck Molecular Force Field
11	R _g	Radius of gyration
12	RMSD	Root-mean-square deviation
13	SASA	Solvent accessible surface area
14	UFF	Universal Force Field
15	ΔG	Binding energy
16	APP	Amyloid precursor protein
17	TPSA	Total polar surface areas
18	VDs	Volumes of distribution
19	F _u	Fraction unbound
20	ADMET	Absorption, Distribution, Metabolism, Excretion, and Toxicity
21	AGEs	Advanced Glycation End Products
22	ROS	Reactive oxygen species

1 **1. Introduction**

2 The precise mechanisms that initiate and drive the progression of Alzheimer's disease
3 (AD) remain elusive. Among the clinical hallmarks of AD is the misfolding of agglomerated
4 β -Amyloid ($A\beta$) proteins and their subsequent accumulation in neurons (Itoh et al., 2022).
5 These aggregated $A\beta$ peptides further organize into different oligomers of cross- β -sheet
6 fibrils, a process that generates extrinsically insoluble plaques (Kurkinen et al., 2023). The
7 formation of these senile aggregates is primarily driven by $A\beta_{1-40}$ fibrils, although $A\beta_{1-42}$
8 species are particularly toxic due to their inherent propensity to self-assemble (Abedin et al.,
9 2021).

10 Botanicals have been a cornerstone of traditional medicine for centuries. Numerous
11 studies highlight the potential of phytochemicals, particularly polyphenols, in addressing
12 neurological conditions like AD (Muscat et al., 2020). These antioxidants can potentially
13 impede Alzheimer's progression by inhibiting amyloid fibril formation (Sinyor et al., 2020).
14 Date palm trees (*Phoenix dactylifera* L.), significant in Egyptian and Middle Eastern
15 pharmacopeia, have versatile medicinal uses (Anwar et al., 2022). The Ajwa cultivar,
16 indigenous to Saudi Arabia, contains sugars, minerals, vitamins, and various bioactive
17 substances. Traditionally, Ajwa dates are valued for their anti-oxidative, anti-microbial, anti-
18 inflammatory, hepatoprotective, anti-cancer, and cardiovascular benefits (Aljuhani et al.,
19 2019; Fernández-López et al., 2022).

20 Machine learning and computational tools represent cutting-edge methods for
21 discovering pharmaceutical agents from botanical sources for managing AD. Molecular
22 simulations predict binding affinities and interactions between compounds and AD-related
23 target proteins, aiding in the identification of promising lead molecules (Gupta and
24 Dasmahapatra, 2020). In a previous study, we investigated the effect of date fruit botanicals
25 on $A\beta_{1-40}$ fibrils (Zia et al., 2022). However, it is known that the main culprits in AD are $A\beta_{1-}$
26 $_{42}$ fibrils. Thus, our current research focuses on the anti-amyloidogenic properties of
27 phytonutrients from date palms against $A\beta_{1-42}$ fibrils using in-silico methods. We performed
28 docking analysis to identify optimal ligands and used molecular dynamics to assess their
29 binding affinity and stability. **We used three distinct conformers of $A\beta_{1-42}$ to gain insights into
30 the binding interactions between the botanicals and the fibril. Understanding the binding
31 affinities of ligands for each conformer of the $A\beta$ protein can help design targeted
32 therapeutics for AD.**

1

2 **2. Methodologies**

3 *2.1. Preparation of proteins and ligands*

4 The 3-D coordinates of target peptides (2BEG: 3D structure of A β ₁₋₄₂ proto-filament,
5 2MXU: a S-shaped 42-residue β -amyloid dodecamer, and 2NAO: a disease-relevant A β ₁₋₄₂
6 amyloid fibril) were acquired from the PDB RCSB database (<https://www.rcsb.org>).
7 AutoDock Tools (ADT) (<https://autodocksuite.scripps.edu/adt/>) was employed to prepare
8 protein for molecular docking by adding Kollman charges. The structure file of target
9 proteins does not include any water or hetero atoms. Finally, Merck Molecular Force Field
10 (MMFF) was used to reduce the energy of protein molecules. The 2D structures of ligands
11 were downloaded from PubChem (Table 1) (<https://pubchem.ncbi.nlm.nih.gov>). Ligands
12 were optimized for docking process by designating bond ordering and degrees using ADT.
13 The component charges of Gasteiger were established. Universal Force Field (UFF) was
14 employed to minimize the energy levels of the selected ligands using PyRx
15 (<https://pyrx.sourceforge.io>).

16 *2.2. Molecular docking studies*

17 Molecular docking was achieved utilizing Autodock-Vina enabled PyRx
18 (<https://pyrx.sourceforge.io>), where the Lamarckian Genetic Algorithm (LGA) was employed
19 as a scoring function (Trott and Olson, 2010). The molecular docking of ligands with target
20 proteins namely 2BEG, 2MXU, and 2NAO was performed inside a grid-box of dimensions
21 (46×23×27), (68×50×66), and (35×70×64) Å, respectively. Energy optimization was
22 performed using PyRx's built-in utilities. The most optimal configuration of each 'protein-
23 ligand complex' was created and evaluated using Discovery Studio 2020 (BIOVIA)
24 (<https://discover.3ds.com/discovery-studio-visualizer-download>). The ligands' dissociation
25 coefficient (K_d) for the target protein was determined from binding energy (ΔG) employing
26 the following formula (Rehman et al., 2014):

$$\Delta G = -RT \ln K_d \quad (1)$$

27 where, R and T are Boltzman's gas constant and temperature, respectively.

28 *2.3. Molecular dynamics simulation*

29 The stability of the 2BEG-Diosmetin, 2MXU-Rutin, and 2NAO-Genistein complexes
30 was evaluated using GROMACS 2022.4 (<https://zenodo.org/records/6451564>) for molecular
31 dynamics (MD) simulations. Protein structures were generated with the CHARMM36 force

1 field and TIP3P water models, and the CHARMM General Force Field (CGenFF) was used
2 for the compounds. Simulations were carried out in a dodecahedron-shaped box with the
3 protein-ligand complex centered and at least 1.0 nm from the edges, using TIP3P water and
4 Na⁺ or Cl⁻ ions to neutralize and mimic physiological conditions with 150 mM NaCl. Energy
5 minimization involved up to 50,000 "steepest descent" steps. The system was equilibrated in
6 NVT and NPT ensembles at 300 K and 1.0 bar, respectively, with temperature and pressure
7 controlled by the Berendsen thermostat and Parrinello-Rahman barostat. A 100 ns production
8 run was performed with a 2-fs time step using the Leapfrog integrator and LINCS for
9 constraints, with a van der Waals cutoff of 1.2 nm. Results were analyzed and presented as
10 means with standard deviations, based on triplicate studies.

11 2.4. Determination of physicochemical and ADMET properties

12 The physicochemical and ADMET (Absorption, Distribution, Metabolism, Excretion,
13 and Toxicity) properties of the selected compounds were analyzed using the pkCSM web
14 server, (<https://biosig.lab.uq.edu.au/pkcsm/>). The pkCSM tool provided predictions for key
15 properties such as molecular weight, logP, and aqueous solubility, along with evaluations of
16 critical pharmacokinetic parameters like gastrointestinal absorption, blood-brain barrier
17 permeability, and hepatotoxicity (Pires et al., 2015).

18 2. Results and discussion

19 In AD, A β peptide variants generated from the breakdown of the Amyloid precursor
20 protein (APP) form the core of insoluble plaques (Henning-Knechtel et al., 2020). In humans,
21 two prominent isoforms stand out: A β ₁₋₄₀ and A β ₁₋₄₂, of which A β ₁₋₄₂ is of relevance to AD.
22 An augmented A β ₁₋₄₂/A β ₁₋₄₀ ratio triggers the formation of A β amyloid fibrils, fostering
23 neurotoxicity, and inducing tau pathology, culminating in neurodegeneration (Breijyeh and
24 Karaman, 2020). Given the intricate interactions, A β ₁₋₄₂ serves as our selected model protein.
25 To account for the protein's diverse conformations, we have opted to focus our investigations
26 on three distinct conformers (PDB Ids: 2BEG, 2MXU, and 2NAO) of the same target, A β ₁₋₄₂.
27 This inclusive approach aims to unravel the complex interplay between protein structures and
28 the factors that contribute to AD pathology.

29 2.1. Molecular docking study

30 The validity of the docking method utilized in this investigation was established
31 through a validation process involving the molecular docking between 2NAO and a known
32 compound, namely CID_9998128. Our findings demonstrated that CID_9998128 occupied

1 the identical binding site on 2NAO, consistent with earlier reports (Thai et al., 2018). The
2 interaction of CID_9998128 with amino acid residues, including Phe4, His6, Ser8, Gly9,
3 Tyr10, Glu11, Val12, and His13 of chains D, E, and F, was observed. The compound
4 CID_9998128 established three conventional hydrogen bonds and seven hydrophobic
5 interactions (such as Pi-Pi T-shaped, Pi-Pi Stacked, Alkyl, and Pi-Alkyl). Given the
6 reproducibility of these results with the previously published report (Thai et al., 2018), it
7 suggests that the in-silico docking principle employed in this investigation is indeed valid.
8 The analyses of molecular docking of target proteins with natural compounds suggest that all
9 the studied ligands were bound between different filaments of the A β ₁₋₄₂ fiber (**Table 1,**
10 **Figures 1-3**). The docking energy of ligands was in the range of -4.7 to -7.2 kcal mol⁻¹, -4.8
11 to -8.2 kcal mol⁻¹, and -5.0 to -8.0 kcal mol⁻¹ for 2BEG, 2MXU, and 2NAO, respectively. In
12 addition, docking energies of the most promising compounds namely Diosmetin, Rutin, and
13 Genistein were calculated using the Glide SP module (Schrodinger, LLC, NY, USA), as
14 reported earlier (AlAjmi et al., 2018). For the 2BEG target, the energies were -7.9, -7.2, and -
15 7.6 kcal mol⁻¹ for Diosmetin, Rutin, and Genistein, respectively. For the 2MXU target, the
16 energies were -7.8, -8.9, and -8.1 kcal mol⁻¹, respectively. For the 2NAO target, the energies
17 were -7.7, -7.5, and -7.9 kcal mol⁻¹, respectively.

18 Amongst the studied ligands, Diosmetin, Rutin, and Genistein displayed the lowest
19 docking energy towards 2BEG, 2MXU, and 2NAO, respectively. Diosmetin, a bioactive
20 flavonoid, has potential therapeutic applications including anti-inflammatory, anti-oxidant,
21 anti-microbial, and analgesic effects (Garg et al., 2022). Further, Genistein, an isoflavone
22 from legumes, exhibits anti-oxidant, anti-inflammatory, anti-proliferative, and anti-microbial
23 properties (Khan et al., 2022). Rutin, a flavonol, is known for its anti-oxidant, cytoprotective,
24 anti-carcinogenic, neuroprotective, and cardioprotective properties (Ganeshpurkar and Saluja,
25 2017). Flavonoids like Genistein (AlFaris et al., 2021) and rutin (Al Juhaimi et al., 2018)
26 have been reported in Saudi Arabian dates, while Diosmetin derivatives have been extracted
27 from date palms using UPLC/MS/MS techniques (Alshwyeh, 2020).

28 The 2BEG-Diosmetin pair was held by two standard hydrogen bonds (E:Val39:HN,
29 and E:Val18:O), and ten hydrophobic interactions with E:Leu17:CD2 (one Pi-Sigma
30 interaction), C:Phe19 (one Pi-Pi T-Shaped interaction), D:Phe19 (two Pi-Pi T-Shaped
31 interactions), E:Phe19 (one Pi-Pi T-Shaped interaction), E:Leu17 (one Pi-Alkyl interaction),
32 E:Val40 (one Pi-Alkyl interaction), D:Val17 (one Pi-Alkyl linkage), D:Val40 (one Pi-Alkyl
33 linkage), and E:Val40 (one Pi-Alkyl interaction) (**Figure 1, Table 2**). Further, Diosmetin

1 formed several van der Waals' interactions with B:Phe19, C:Leu17, C:Val18, C:Val40,
2 D:Gly38, E:Gly37, and E:Gly38. The docking energy of the 2BEG:Diosmetin complex is -
3 7.2 kcal mol⁻¹, corresponding to 1.91×10^5 M⁻¹.

4 The 2MXU-Rutin system was stabilized by one classical hydrogen linkage with
5 C:Gly33:HN, and one carbon-hydrogen bond with C:His14:CE1 (Figure 2A, 2B). The
6 complex was also stabilized by six hydrophobic linkages with C:Ile32-CD1 (one Pi-Sigma
7 interaction), C:His14 (one Pi-Pi stacked interaction), C:Gly33:C-O; Leu34:N (one Amide-Pi
8 interaction), D:Val12 (one Alkyl interaction), D:His14 (one Pi-Alkyl interaction), and
9 A:Val12 (one Pi-Alkyl interaction) (Figure 2, Table 2). The system further revealed van der
10 Waals connections with numerous, such as A:Leu17, A:Ile32, A:Gly33, A:Leu34, B:Val12,
11 B:His14, B:Leu17, B:Ile32, B:Gly33, B:Leu34, C:Val12, C:Leu34, D:Leu17, D:Ile32,
12 D:Gly33, E:His14, and E:Leu17. The binding free energy of the 2MXU-Rutin combination
13 was -8.2 kcal mol⁻¹, consistent with the dissociation constant of 1.03×10^6 M⁻¹ (Table 2).
14 Furthermore, the 2NAO-Genistein complex was stabilized by six conventional hydrogen
15 bonds with A:Tyr10:O, A:His13:HD1, A:His14:HN, A:Gln15:O, B:His14:HN, and
16 B:His14:O; and three hydrophobic interactions with B:Val12:CG2 (Pi-Sigma interaction),
17 A:Lys16, (Pi-Alkyl interactions) and B:Lys16 (Pi-Alkyl interactions) (Figure 3, Table 2).
18 Genistein also established several van der Waals' connections such as A:Ser8, A:Gly9,
19 A:Glu11, B:Tyr10, B:His13, and B:Gln15. The docking energy of the 2NAO-Genistein
20 interaction was -8.0 kcal mol⁻¹, equivalent to a dissociation constant of 7.37×10^5 M⁻¹ (Table
21 2).

22 2.2. Molecular dynamics simulation

23 2.2.1. Root mean square deviation (RMSD)

24 The RMSD value of a protein-ligand pair is commonly used to assess the complex's
25 durability and dynamical character. Thus, we calculated the RMSD of targeted peptides
26 combined with their respective ligand over a time duration of 100 ns (Figure 4). The RMSD
27 of 2BEG alone displayed some fluctuation during the first 0-15 ns and then achieved
28 symmetry from 20 ns onwards. Also, the RMSD of 2BEG in conjunction with Diosmetin
29 stayed constant during the 20-100 ns simulation time, suggesting the unchanging character of
30 the 2BEG-Diosmetin pair. The mean RMSD values of 2BEG alone, and 2BEG-Diosmetin
31 complex during 20-100 ns were 5.48 ± 0.32 Å, and 6.89 ± 0.48 Å respectively (Figure 4A).

1 Likewise, the RMSD of 2MXU alone displayed some fluctuation during 0-10 ns,
2 afterward attaining stability. The RMSD of 2MXU in the presence of Rutin showed some
3 variation during 0-20 ns and then continued to be steady across 20-100 ns simulation time,
4 hinting at the complex's stability. The mean RMSD estimates of 2MXU only, and 2MXU-
5 Rutin conjugate during 20-100 ns were $5.97 \pm 0.26 \text{ \AA}$, and $6.07 \pm 0.37 \text{ \AA}$ respectively (**Figure**
6 **4B**). Furthermore, the RMSD of 2NAO alone or in the presence of Genistein was consistent
7 during the whole MS study. The mean RMSD estimates of 2NAO only, and 2NAO-Genistein
8 conjugate during 0-100 ns were found to be $2.14 \pm 0.13 \text{ \AA}$, and $1.88 \pm 0.09 \text{ \AA}$, respectively
9 (**Figure 4C**). During the MD simulation, the steady RMSD values indicated the formation of
10 a strong association between the protein and its ligand. Furthermore, it revealed that there
11 existed no significant alterations in the overall conformation of the peptide-ligand system.

12 2.2.2. Radius of gyration (Rg) and solvent accessible surface area (SASA)

13 The Rg represents the peptide-ligand's compact dimensions, whereas the SASA
14 evaluates the protein-ligand complex's interaction with liquid. Each of them, consequently,
15 offers details on the resilience of the peptide-ligand composite during the MS study. Herein,
16 the Rg of 2BEG, 2MXU, and 2NAO was evaluated in combination with their respective
17 ligands i.e. Diosmetin, Rutin, and Genistein respectively (**Figure 5A**). The Rg of 2BEG-
18 Diosmetin, 2MXU-Rutin, and 2NAO-Genistein conjugates varied from 4.14-5.16 \AA , to 4.43-
19 4.91 \AA , and 4.52-4.64 \AA respectively, with a mean value of $4.58 \pm 0.34 \text{ \AA}$, $4.86 \pm 0.17 \text{ \AA}$ and
20 $4.57 \pm 0.06 \text{ \AA}$, respectively (**Figure 5A**). The SASA of 2BEG, 2MXU, and 2NAO in the
21 company of their respective ligands i.e. Diosmetin, Rutin, and Genistein during 20-100 ns
22 simulation fluctuated in the range of 423.4-503.7 \AA^2 , 491.7-508.5 \AA^2 , and 444.6-476.4 \AA^2
23 respectively, with a mean of $470.8 \pm 17.3 \text{ \AA}^2$, $478.3 \pm 18.1 \text{ \AA}^2$, and $467.4 \pm 13.9 \text{ \AA}^2$
24 correspondingly (**Figure 5B**). The robustness of the protein-ligand complex is confirmed by
25 these data, which show that the differences in Rg and SASA of 2BEG, 2MXU, and 2NAO
26 combined with their respective ligands did not diverge considerably.

27 2.2.3. Total number of contacts between proteins and ligands

28 The overall number of permanent connections that are generated between a specific
29 protein and its binding partner determines how strong the system is. Here, the complete set of
30 interactions between 2BEG and Diosmetin, 2MXU and Rutin, as well as 2NAO and
31 Genistein over simulation time was computed (**Figure 6**). In 2BEG-Diosmetin system, the
32 total number of contacts varied in the 1-15 range, with no less than 7 contacts. Likewise, the

1 total contacts between 2MXU and Rutin varied from 3-14, with an average of 8 contacts.
2 Further, the contacts between 2NAO and Genistein were in the range of 0-9, with an average
3 of 4 interacting regions. These findings point to the establishment of a persistent ligand-
4 protein combination.

5 The A β peptide exists in several polymorphic forms; each characterized by a unique
6 conformation and motif (Miller et al., 2010). Numerous pivotal conformational features of
7 A β ₁₋₄₂ fibrils are now available. For example, A β ₁₋₄₂ fibrils can form a trifold- β pattern
8 consisting of three separate overlapping parallel β -sheets (Xiao et al., 2015). Alternatively,
9 they can also adopt a β -sheet- β -turn- β -sheet motif, featuring two inter-molecular, parallel,
10 and in-register β -strands (Lührs et al., 2005). In our investigation, the model peptides 2MXU
11 and 2NAO are S-shaped dodecamers and trimer respectively, whereas 2BEG is a U-shaped
12 fibril. In addition, it was discovered that the residues including Val12, His13, His14, Lys16,
13 Leu 17, Phe19, Ile32, Gly33, Leu34, and Val40 interacted actively with the ligands (**Table**
14 **2**), which are in concordance with previous studies (Kuang et al., 2015; Xi et al., 2016). In
15 2BEG protofilament, the residues Leu134, Phe19, Val36, and Ala21 of one β -sheet mediate
16 the hydrophobic intermolecular contacts with the even-numbered residues of a parallel β -
17 strand (Petkova et al., 2002). Residue pair Asp23-Lys28, connects these two strands via an
18 intermolecular salt bridge, contributing to the overall stability of the “U” shape of the
19 protofibril (Jarmuła et al., 2022). Further, a framework of inter-and intra-strand connections
20 stabilizes this U-shaped proto-fibril. Notably, this network includes a π - π interaction
21 involving the aromatic rings of internally present F19 and F20 located on the exterior of the
22 peptide (Ahmed et al., 2010). In our study, Phe19 is involved in binding the ligand via π - π
23 hydrophobic interaction, while Leu17 and Val40 form π -Alkyl bonding with the Diosmetin
24 (**Figure 1**).

25 The 3-D conformation of 2MXU significantly deviates from a typical β -loop- β motif
26 generally obtained in high-resolution structures of A β ₁₋₄₀ peptides. For example, in the 2MXU
27 conformer, specific side chains interactions like those concerning Phe19 and Leu34 that are
28 previously reported in solid state NMR spectra of A β ₁₋₄₂ fibrils, are lacking (Villalobos
29 Acosta et al., 2018). Moreover, cross-peaks of several key residues including Val12, His13,
30 and His14 are also absent from the spectra (Lührs et al., 2005). Interestingly, in this study,
31 these residues are shown to be involved in strong binding with the ligand through H-bond
32 (His14) or Pi-Alkyl interaction (Val12) (**Figure 2**). Additionally, the 2MXU-fibril structure
33 reveals the presence of an ionic bond between the amino moiety of Lys28 and the C terminus

1 of Ala42 (Xiao et al., 2015); this interaction is absent in A β ₁₋₄₀ fibrils. In the secondary
2 structure, Gly33 is present at the loop region connecting the three β -strands, one of which
3 involves residues from Val12 to Phe20. We observed that Gly33 interacts with several atoms
4 of Rutin via both H-bonding and amide-Pi stacked hydrophobic interactions (**Figure 2**).

5 In the 2NAO structure, residues 1–14 are organized in a β -sheet, while residues 15–42
6 **construct** a cross- β -sheet with hidden hydrophobic side chains. For both A β ₁₋₄₂ peptide types
7 A and B, inter-sheet salt bridges involving Lys16, Glu22, and Ala42 stabilize the structure by
8 linking separate cross- β sheets. Additionally, Met35 of one β -sheet interacts with Leu17 or
9 Gln15 from the second β -strand (Villalobos Acosta et al., 2018). Our research identified
10 hydrogen bonding between the ligand and charged residues His16, His13, and Gln15, with
11 Lys16 engaging in Pi-Alkyl interactions with Genistein (**Figure 3**).

12 As a rule, the lower the docking energy, the better a ligand's binding affinity. The
13 docking scores in **Table 2** reveal that the 2NAO and 2MXU peptides have high binding
14 affinity for the ligands, while 2BEG shows the lowest binding energy. Both 2NAO and
15 2MXU fibrils are stabilized by strong hydrogen bonds and significant hydrophobic
16 interactions (π -Alkyl and π -Sigma). Previous studies noted that high docking scores were due
17 to pi-pi stacking (in His14), hydrogen bonding between the ligand's amine and Gly33, and
18 hydrophobic interactions with residues Val12, Leu17, Leu34, and Ile32 (Maronedze et al.,
19 2020). In contrast, 2BEG's stability relies mainly on hydrophobic interactions, with minimal
20 hydrogen bonding, which may account for the lower binding affinity of Diosmetin.

21 3.3. Prediction of Physicochemical Properties, and Drug-Likeness Potential

22 Molecular descriptors provide critical insights into the pharmacokinetic and
23 pharmacodynamic properties of compounds, key for evaluating their drug candidacy.
24 Diosmetin, Rutin, and Genistein have molecular weights of 300.27, 610.52, and 270.24 g/mol
25 respectively (**Table 3**), highlighting significant variations in size that could impact their
26 pharmacokinetics. Their LogP values range from -1.69 to 2.58, reflecting differences in lipid
27 solubility that might affect their absorption and membrane permeability. The compounds also
28 differ in structural flexibility, with rotatable bonds ranging from 1 to 6, suggesting they can
29 adopt various conformations that could influence receptor binding. Hydrogen bonding
30 capacities vary, with Diosmetin, Rutin, and Genistein having between 3 and 10 hydrogen
31 bond donors and 5 to 16 acceptors, affecting their potential to form bonds with other
32 molecules. The total polar surface areas (TPSA) of these compounds range from 112.52 to

1 240.90 Å², indicating differences in solubility and interactions with aqueous environments
2 (**Table 3**). These diverse molecular characteristics underscore the unique biological activities
3 and therapeutic potentials of each compound, highlighting the importance of understanding
4 these properties in drug development.

5 3.4. Analysis of ADMET properties

6 The ADMET analysis of Diosmetin, Rutin, and Genistein highlights their potential as
7 therapeutic agents (**Table 3**). Their solubility values of -3.238, -2.892, and -3.595 mol/L
8 suggest good bioavailability. Caco-2 permeability results show Diosmetin (0.326×10^{-6} cm/s)
9 and Genistein (0.900×10^{-6} cm/s) have better potential for oral absorption than Rutin, which
10 has a negative value. This is reflected in their intestinal absorption rates: Diosmetin at 79.9%,
11 Rutin at 23.4%, and Genistein at 93.4%, indicating Rutin's lower efficiency. All three
12 compounds have a similar skin permeability value of -2.735, suggesting comparable potential
13 for topical use. They are substrates for P-glycoprotein but do not inhibit P-glycoprotein I or
14 II, minimizing concerns about drug interactions.

15 Regarding distribution, Diosmetin (0.709 L/Kg) and Rutin (1.663 L/Kg) have higher
16 volumes of distribution compared to Genistein (0.094 L/Kg), indicating more extensive body
17 distribution for Rutin (**Table 3**). The fraction unbound (Fu) values are 0.068 for Diosmetin,
18 0.187 for Rutin, and 0.087 for Genistein, suggesting that Rutin **has a higher proportion of**
19 **unbound drug** in the plasma, which could enhance its activity but also increase the risk of
20 drug interactions. Metabolically, Diosmetin inhibits CYP1A2, CYP2C19, and CYP2C9,
21 while Genistein inhibits CYP1A2 and CYP2C19. These interactions may affect the
22 metabolism of other drugs, necessitating careful consideration in combination therapies.
23 None of the compounds show AMES toxicity or hepatotoxicity. Diosmetin, Rutin, and
24 Genistein have clearance rates of 0.598 ml/min/kg, -0.369 ml/min/kg, and 0.151 ml/min/kg,
25 respectively. Rutin's negative clearance rate suggests possible elimination issues, and its
26 inhibition of hERG II channels may pose a risk of cardiotoxicity, warranting further
27 investigation (**Table 3**).

28 Diosmetin and Genistein exhibit favorable pharmacokinetic profiles for oral use,
29 owing to their higher permeability and absorption rates. Conversely, Rutin's lower absorption
30 rate could limit its effectiveness. Enhancing Rutin's bioavailability and validating these
31 results in vivo are needed. While Diosmetin, Rutin, and Genistein show promising safety
32 profiles with no hepatotoxicity or skin sensitization, further investigation is necessary to

1 assess metabolic interactions and Rutin's potential cardiotoxicity to ensure their clinical
2 safety and efficacy.

3 3.5. *Potential mechanism of action*

4 The therapeutic action of date palm is believed to stem from its diverse botanicals
5 with various physiological effects. Some compounds directly inhibit A β fibril formation. For
6 example, flavonoids like resveratrol can prevent A β ₁₋₄₂ fibril formation and convert the
7 peptide into non-toxic aggregates (Phan et al., 2019). Diosmetin reduces A β accumulation by
8 protecting against AGEs-induced ROS, downregulating A β production, and promoting its
9 degradation (Lai et al., 2022). Rutin improves cognitive function in mice by reducing tau
10 deposits and modulating its phosphorylation (Sun et al., 2021). Genistein protects against A β
11 toxicity by inhibiting protein kinase B inactivation and tau hyperphosphorylation (Petry et al.,
12 2020). Further, Ren et al (Ren et al., 2018) demonstrated that it also acts as a dual inhibitor of
13 A β and hIAPP aggregation and has shown potential in crossing the blood-brain barrier to
14 reduce A β -related neurotoxicity in vivo (Duan et al., 2021). These findings suggest that date
15 palm metabolites have potential as treatments for Alzheimer's disease, but further research is
16 needed to clarify the specific roles and mechanisms of each flavonoid.

17 3.6. *Limitations of the study*

18 Computational approaches offer significant potential to streamline drug development
19 and clinical research, reducing the need for animal models and human trials while predicting
20 toxicities more efficiently. Molecular simulations, key to these methods, can predict binding
21 affinities and interactions with Alzheimer's-related proteins. However, molecular docking has
22 limitations, including limited ligand and receptor conformation sampling and reliance on
23 estimated scoring algorithms, which may not always align with experimental results.
24 Moreover, it is important to note that the docking and simulation studies were performed in
25 isolation, without considering the presence of other biomolecules. These studies do not mimic
26 the cellular milieu as interactions inside the cell are different from those encountered in the
27 lab. Therefore, in vitro as well as in vivo studies are required to validate the findings of the
28 present study.


29 4. **Conclusions**

30 Given the strong link between A β ₁₋₄₂ aggregation and Alzheimer's disease (AD)
31 pathogenesis, our study evaluated the anti-aggregation potential of phytochemicals present in
32 Ajwa dates. The molecular docking and dynamics simulation results validate the

1 effectiveness of Diosmetin, Rutin, and Genistein in binding to A β ₁₋₄₂ fibrils, with low docking
2 energies indicating strong binding affinities. Among the three, Diosmetin exhibited the most
3 stability in complex with 2BEG, while Rutin and Genistein showed stronger interactions with
4 2MXU and 2NAO, respectively. The stability of these complexes was supported by
5 consistent RMSD, Rg, and SASA values and a significant number of persistent contacts
6 during the simulation. Additionally, the analysis of **physiochemical and** ADMET properties
7 suggests these compounds have favorable drug-like characteristics, with varied
8 pharmacokinetics and safety profiles, highlighting their potential as therapeutic agents.
9 However, further studies are necessary to fully explore their neuroprotective potential and in
10 vivo efficacy.

11 **Figure legends**


12
13 **Figure 1:** Molecular docking of Diosmetin with 2BEG. (A) 2D docking pose, (B) 3D
14 docking pose, and (C) Molecular interaction between 2BEG and Diosmetin.
15 **Figure 2:** Molecular docking of Rutin with 2MXU. (A) 2D docking pose, (B) 3D docking
16 pose, and (C) Molecular interaction between 2MXU and Rutin.
17 **Figure 3:** Molecular docking of Genistein with 2NAO. (A) 2D docking pose, (B) 3D docking
18 pose, and (C) Molecular interaction between 2NAO and Genistein.
19 **Figure 4:** Molecular dynamics simulation 2BEG, 2MXU, and 2NAO with their respective
20 bioactive compounds Diosmetin, Rutin, and Genistein. (A) Root mean square deviation
21 (RMSD) of 2BEG in the absence and presence of Diosmetin, (B) RMSD of 2MXU in the
22 absence and presence of Rutin, and (C) RMSD of 2NAO in the absence and presence of
23 Genistein.
24 **Figure 5:** (A) Radius of gyration, and (B) Solvent accessible surface area (SASA) of 2BEG,
25 2MXU, and 2NAO in the absence and presence of Diosmetin, Rutin, and Genistein.
26 **Figure 6:** Variation in total number of contacts between proteins and ligands. (A) 2BEG-
27 Diosmetin, (B) 2MXU-Rutin, and (C) 2NAO-Genistein complexes.



11
Figure 1

1


2



1


Figure 2

2




1

Figure 3



1

Figure 4



1

Figure 5




Figure 6

1
2

Table 1. Molecular docking scores of selected palm date phytochemicals with different conformers of A β ₁₋₄₂.

S. No.	Ligand	ID Number	Formula	Docking Energy (kcal/mol)		
				2BEG	2MXU	2NAO
1.	Apigenin	5280443	C ₁₅ H ₁₀ O ₅	-6.3	-7.2	-7.4
2.	Cianidanol	9064	C ₁₅ H ₁₄ O ₆	-6.3	-6.8	-6.9
3.	Daidzein	5281708	C ₁₅ H ₁₀ O ₄	-5.7	-6.8	-6.9
4.	Diosmetin	5281612	C ₁₆ H ₁₂ O ₆	-7.2 (-7.9)*	-7.4 (-7.8)*	-6.2 (-7.7)*
5.	Ferulic acid	445858	C ₁₀ H ₁₀ O ₄	-6.0	-5.3	-5.4
6.	Formononetin	5280378	C ₁₆ H ₁₂ O ₄	-6.7	-7.1	-6.9
7.	Gallic acid	370	C ₇ H ₆ O ₅	-4.7	-4.9	-5.1
8.	Genistein	5280961	C ₁₅ H ₁₀ O ₅	-6.2 (-7.6)*	-6.8 (-8.1)*	-8.0 (-7.9)*
9.	Glycitein	5317750	C ₁₆ H ₁₂ O ₅	-6.2	-7.2	-7.6
10.	Luteolin	5280445	C ₁₅ H ₁₀ O ₆	-6.1	-7.3	-7.6
11.	Quercetin	5280343	C ₁₅ H ₁₀ O ₇	-5.9	-7.1	-7.0
12.	Rutin	5280805	C ₂₇ H ₃₀ O ₁₆	-6.2 (-7.2)*	-8.2 (-8.9)*	-6.8 (-7.5)*
13.	Sinapic acid	637775	C ₁₁ H ₁₂ O ₅	-5.6	-5.5	-6.7
14.	Vanillic acid	8468	C ₈ H ₈ O ₄	-5.4	-4.8	-5.0

* The values in the parenthesis are calculated using Glide SP module of Schrodinger software (LLC, NY, USA).

1 **Table 2.** Molecular interaction between selected palm date phytochemicals and different
 2 conformers of Aβ₁₋₄₂.

Interaction between donor and acceptor atoms	Distance (Å)	Nature of interaction	Binding energy (ΔG), kcal M ⁻¹	Binding affinity (K _d), M ⁻¹
2BEG-Diosmetin				
E:VAL39:HN - LIG:O	2.9424	Conventional Hydrogen Bond	-7.2	1.91 × 10 ⁵
LIG:H - E:VAL18:O	2.1186	Conventional Hydrogen Bond		
E:LEU17:CD2 - LIG	3.2196	Hydrophobic (Pi-Sigma)		
C:PHE19 - LIG	5.1366	Hydrophobic (Pi-Pi T-shaped)		
D:PHE19 - LIG	4.3641	Hydrophobic (Pi-Pi T-shaped)		
D:PHE19 - LIG	5.3534	Hydrophobic (Pi-Pi T-shaped)		
E:PHE19 - LIG	4.5794	Hydrophobic (Pi-Pi T-shaped)		
LIG - E:LEU17	5.0995	Hydrophobic (Pi-Alkyl)		
LIG - E:VAL40	5.0625	Hydrophobic (Pi-Alkyl)		
LIG - D:LEU17	4.8759	Hydrophobic (Pi-Alkyl)		
LIG - D:VAL40	5.4053	Hydrophobic (Pi-Alkyl)		
LIG - E:VAL40	5.2489	Hydrophobic (Pi-Alkyl)		
2MXU-Rutin				
C:GLY33:HN - LIG:O	2.6673	Conventional Hydrogen Bond	-8.2	1.03 × 10 ⁶
C:HIS14:CE1 - LIG:O	3.5188	Carbon Hydrogen Bond		
C:ILE32:CD1 - LIG	3.9196	Hydrophobic (Pi-Sigma)		
C:HIS14 - LIG	4.8478	Hydrophobic (Pi-Pi Stacked)		
C:GLY33:C:O; LEU34:N - LIG	5.6050	Hydrophobic (Amide-Pi Stacked)		
LIG:C - D:VAL12	4.7258	Hydrophobic (Alkyl)		
D:HIS14 - LIG:C	5.2573	Hydrophobic (Pi-Alkyl)		
LIG - A:VAL12	5.3754	Hydrophobic (Pi-Alkyl)		
2NAO-Genistein				
A:HIS13:HD1 - LIG:O	2.5571	Conventional Hydrogen Bond	-8.0	7.37 × 10 ⁵
A:HIS14:HN - LIG:O	2.9847	Conventional Hydrogen Bond		
B:HIS14:HN - LIG:O	2.8596	Conventional Hydrogen Bond		
LIG:H - A:GLN15:O	1.9206	Conventional Hydrogen Bond		
LIG:H - B:HIS14:O	2.7283	Conventional Hydrogen Bond		
LIG:H - A:TYR10:O	2.4852	Conventional Hydrogen Bond		
B:VAL12:CG2 - LIG	3.9002	Hydrophobic (Pi-Sigma)		
LIG - A:LYS16	5.1099	Hydrophobic (Pi-Alkyl)		
LIG - B:LYS16	4.4031	Hydrophobic (Pi-Alkyl)		

3

1 **Table 3.** Physicochemical and ADMET properties of Diosmetin, Rutin, and Genistein.

Property		Diosmetin	Rutin	Genistein
Physicochemical	Molecular Weight, g/mol	300.27	610.52	270.24
	Partition coefficient, LogP	2.58	-1.69	2.58
	Number of rotatable bonds	2	6	1
	Number of H-bond acceptors	6	16	5
	Number of H-bond donors	3	10	3
	Topological polar surface area, Å ²	123.99	240.90	112.52
Absorption	Water solubility (mol/L)	-3.238	-2.892	-3.595
	Caco2 permeability (10 ⁻⁶ , cm/s)	0.326	-0.949	0.900
	Intestinal absorption (human), %	79.9	23.4	93.4
	Skin Permeability (log Kp)	-2.735	-2.735	-2.735
	P-glycoprotein substrate	Yes	Yes	Yes
	P-glycoprotein I inhibitor	No	No	No
	P-glycoprotein II inhibitor	No	No	No
Distribution	VDss (human), log L/Kg	0.709	1.663	0.094
	Fraction unbound (human), Fu	0.068	0.187	0.087
	BBB permeability, log BB	-0.954	-1.899	-0.710
	CNS permeability, log PS	-2.316	-5.178	-2.048
Metabolism	CYP2D6 substrate	No	No	No
	CYP3A4 substrate	No	No	No
	CYP1A2 inhibitor	Yes	No	Yes
	CYP2C19 inhibitor	Yes	No	Yes
	CYP2C9 inhibitor	Yes	No	No
	CYP2D6 inhibitor	No	No	No
	CYP3A4 inhibitor	No	No	No
Excretion	Total Clearance, log ml/min/Kg	0.598	-0.369	0.151
	Renal OCT2 substrate	No	No	No
Toxicity	AMES toxicity	No	No	No
	Max. tolerated dose (human), log mg/Kg/day	0.420	0.452	0.478
	hERG I inhibitor	No	No	No
	hERG II inhibitor	No	Yes	No
	Hepatotoxicity	No	No	No
	Skin Sensitization	No	No	No

2

ORIGINALITY REPORT

10%

SIMILARITY INDEX

9%

INTERNET SOURCES

10%

PUBLICATIONS

4%

STUDENT PAPERS

PRIMARY SOURCES

1	chemrxiv.org Internet Source	2%
2	www.ncbi.nlm.nih.gov Internet Source	1%
3	Mohammed B. Alshammari, Akil Ahmad, Anamika Gupta, Qamar Zia et al. "Photochemical Degradation and In-Silico Studies of Venlafaxine: A Photosensitizing Antidepressant Drug", Arabian Journal for Science and Engineering, 2023 Publication	1%
4	www.mdpi.com Internet Source	1%
5	Ali Oubella, Abdoullah Bimoussa, Md Tabish Rehman, Mohamed F AlAjmi et al. "Molecular hybrids based on 1,2,3-triazole and 1,3,4-thiadiazole cores: Synthesis, characterization, anticancer activity and In silico study", Journal of Molecular Structure, 2024 Publication	1%

6	www.researchsquare.com Internet Source	1 %
7	jbioleng.biomedcentral.com Internet Source	1 %
8	rcastoragev2.blob.core.windows.net Internet Source	1 %
9	Md. Tabish Rehman, Mohamed F. AlAjmi, Afzal Hussain. "Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19", Current Pharmaceutical Design, 2021 Publication	<1 %
10	Alexander Böcker, Pierre R. Bonneau, Oliver Hucke, Araz Jakalian, Paul J. Edwards. "Development of Specific "Drug-Like Property" Rules for Carboxylate-Containing Oral Drug Candidates", ChemMedChem, 2010 Publication	<1 %
11	ia601207.us.archive.org Internet Source	<1 %
12	www.frontiersin.org Internet Source	<1 %
13	www.intechopen.com Internet Source	<1 %

14

Pranav Deepak Pathak, Roshani Raut, Sebastián Jaramillo-Isaza, Pradnya Borkar, Rutvij H. Jhaveri. "Computational Approaches in Bioengineering - Volume 1: Computational Approaches in Biotechnology and Bioinformatics", CRC Press, 2024

Publication

<1 %

15

Daniel Danladi Gaiya, Aliyu Muhammad, Joy Sim Musa, Richard Auta et al. "In silico analysis of Balsaminol as anti-viral agents targeting SARS-CoV-2 main protease, spike receptor binding domain and papain-like protease receptors", Springer Science and Business Media LLC, 2023

Publication

<1 %

16

www.researchgate.net

Internet Source

<1 %

Exclude quotes On

Exclude matches < 14 words

Exclude bibliography On